Related references
Note: Only part of the references are listed.Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia
Hideki Muramatsu et al.
BLOOD (2010)
Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations
Kazuyuki Matsuda et al.
BLOOD (2010)
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
Alfonso Quintas-Cardama et al.
BLOOD (2010)
Gene Expression-Based Classification As an Independent Predictor of Clinical Outcome in Juvenile Myelomonocytic Leukemia
Silvia Bresolin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia
B. Perez et al.
JOURNAL OF MEDICAL GENETICS (2010)
Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia
Charlotte M. Niemeyer et al.
NATURE GENETICS (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back
Katherine A. Rauen et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2009)
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis
Gordon Chan et al.
BLOOD (2009)
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia
Mignon L. Loh et al.
BLOOD (2009)
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
Francis H. Grand et al.
BLOOD (2009)
Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies
Hideki Makishima et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Aberrant GM-CSF signal transduction pathway in juvenile myelomonocytic leukemia assayed by flow cytometric intracellular STAT5 phosphorylation measurement
G. Gaipa et al.
LEUKEMIA (2009)
Juvenile myelomonocytic leukemia: A report from the 2nd International JMML Symposium
Rebecca J. Chan et al.
LEUKEMIA RESEARCH (2009)
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras
Jennifer O. Lauchle et al.
NATURE (2009)
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
Masashi Sanada et al.
NATURE (2009)
Correlation of Clinical Features With the Mutational Status of GM-CSF Signaling Pathway-Related Genes in Juvenile Myelomonocytic Leukemia
Nao Yoshida et al.
PEDIATRIC RESEARCH (2009)
JAK mutations in high-risk childhood acute lymphoblastic leukemia
Charles G. Mullighan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations
Christian Flotho et al.
BLOOD (2008)
Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options
Charlotte Marie Niemeyer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates
Nikesh Kotecha et al.
CANCER CELL (2008)
250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl, in Myeloid Malignancies
Andrew J. Dunbar et al.
CANCER RESEARCH (2008)
Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia
Sophie Archambeault et al.
BLOOD (2008)
Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: A retrospective analysis and definition of response criteria
Eva Bergstraesser et al.
PEDIATRIC BLOOD & CANCER (2007)
Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11
C. Flotho et al.
ONCOGENE (2007)
Targeting RAS signaling pathways in juvenile myelomonocytic leukemia
Christian Flotho et al.
CURRENT DRUG TARGETS (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia
A. Yoshimi et al.
LEUKEMIA (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo
Benjamin S. Braun et al.
BLOOD (2006)
Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies
Karen Stephens et al.
BLOOD (2006)
The Cbl interactome and its functions
MHH Schmidt et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
CP Kratz et al.
BLOOD (2005)
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
S Schubbert et al.
BLOOD (2005)
Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia
A Yoshimi et al.
LEUKEMIA (2005)
Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia
A Yoshimi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor
RJ Chan et al.
BLOOD (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial
F Locatelli et al.
BLOOD (2005)
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations
MG Mohi et al.
CANCER CELL (2005)
Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia
EJ Gratias et al.
PEDIATRIC BLOOD & CANCER (2005)
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
ML Loh et al.
BLOOD (2004)
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder
BS Braun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation
T Araki et al.
NATURE MEDICINE (2004)
Somatic inactivation of Nfl in hematopoietic cells results in a progressive myeloproliferative disorder
DT Le et al.
BLOOD (2004)
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
M Tartaglia et al.
NATURE GENETICS (2003)
Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival
SJ Passmore et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
BG Neel et al.
TRENDS IN BIOCHEMICAL SCIENCES (2003)
Ras processing as a therapeutic target in hematologic malignancies
DT Le et al.
CURRENT OPINION IN HEMATOLOGY (2002)
Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group
A Manabe et al.
LEUKEMIA (2002)
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
M Tartaglia et al.
NATURE GENETICS (2001)
Nf1 and Gmcsf interact in myeloid leukemogenesis
RA Birnbaum et al.
MOLECULAR CELL (2000)